Recent Updates
Recently added Catalysts

XmAb412

Phase 1

Not Applicable - Healthy Adult Participants | Small molecule | Other |Xencor, Inc.|Last Updated: Aug 3, 2026

Target and mechanism

ModalitySmall molecule

Also known as XmAb412 Monoclonal Bispecific Antibody

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLEDDMC
Total Trials1
Total Enrollment128

FDA Designations

No designations recorded

Clinical trial landscape

XmAb412 · 1 trial · 1 indication

Phase 1 1
NCT07713485Study of XmAb412 in Healthy ParticipantsNot Applicable - Healthy Adult Participants
RECRUITING128 Analytics
PHASE1RECRUITING
Study of XmAb412 in Healthy Participants
Not Applicable - Healthy Adult ParticipantsUnlock trial analytics

Study Endpoints

Primary Endpoints

Incidence and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) of XmAb412 in healthy adult participants (Part A and Part B)
Up to 28 weeks

Secondary Endpoints

Serum PK parameters of XmAb412 in healthy adult participants (Part A and Part B)
Up to 28 weeks
Cmax (Maximum concentration of drug)
Up to 28 weeks
Tmax (Time of maximum concentration of drug)
Up to 28 weeks
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelSEQUENTIAL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Part A: Active DrugACTIVE_COMPARATORActive XmAb412 to be administered to healthy adult participants.
Part A: PlaceboPLACEBO_COMPARATORPlacebo Comparator to be administered to healthy participants.
Part B: ActiveACTIVE_COMPARATORActive XmAb412 to be administered to healthy participants.
Part B: PlaceboPLACEBO_COMPARATORPlacebo Comparator to be administered to healthy participants.

Interventions

NameTypeDescription
XmAb412 Monoclonal Bispecific AntibodyDRUGMonoclonal Bispecific Antibody
PlaceboDRUGPlacebo
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 55 Years
SexALL
Healthy VolunteersYes
Study Sites2

Inclusion Criteria: * Age 18-55 years old * Must be in good health with no significant medical history * BMI 18-35 kg/m2 * Contraceptive use consistent with local regulations * Able and willing to provide written informed consent Exclusion Criteria: * Any physical condition that prohibits study c...

Countries:Australia
Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

LOWAug 3, 2026NCT07713485lastUpdatePostDate: changed
LOWAug 3, 2026NCT07713485lastUpdatePostDate: changed
LOWJul 20, 2026NCT07713485NEW_TRIAL: changed
LOWJul 20, 2026NCT07713485NEW_TRIAL: changed